These enhanced CAR T-cells displayed greater cytolytic activity, cytokine production, and proliferation against multiple myeloma cells in the presence of CAFs, surpassing the performance of standard CAR T-cells targeting BCMA as a single antigen [130]. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.